Latest news with #46thAnnualGlobalHealthcareConference
Yahoo
6 hours ago
- Business
- Yahoo
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on and will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at Alkermes Contact: Jamie ConstantineInvestor Relations+1 781 873 2402 View original content to download multimedia: SOURCE Alkermes plc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 hours ago
- Business
- Yahoo
Alkermes to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference
DUBLIN, June 2, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 10:00 a.m. EDT (3:00 p.m. BST). The live webcast may be accessed under the Investors tab on and will be archived for 14 days. About Alkermes plc Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy and idiopathic hypersomnia. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at Alkermes Contact: Jamie ConstantineInvestor Relations+1 781 873 2402 View original content to download multimedia: SOURCE Alkermes plc Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15 hours ago
- Business
- Yahoo
DocGo Announces Upcoming Participation at the Goldman Sachs 46th Annual Global Healthcare Conference
NEW YORK, June 02, 2025--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) ("DocGo"), a leading provider of technology-enabled mobile health and medical transportation services, today announced that Lee Bienstock, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th from 4:00 – 4:35 PM Eastern Time, and hold 1x1 meetings as well. A webcast of the event will be available on the investor relations section of DocGo's website at About DocGo DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for municipalities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote advanced practice provider, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit View source version on Contacts Investors: Mike ir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
15 hours ago
- Business
- Business Wire
DocGo Announces Upcoming Participation at the Goldman Sachs 46 th Annual Global Healthcare Conference
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) ('DocGo'), a leading provider of technology-enabled mobile health and medical transportation services, today announced that Lee Bienstock, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46 th Annual Global Healthcare Conference on Monday, June 9 th from 4:00 – 4:35 PM Eastern Time, and hold 1x1 meetings as well. A webcast of the event will be available on the investor relations section of DocGo's website at About DocGo DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and ambulance services. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for municipalities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote advanced practice provider, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit
Yahoo
4 days ago
- Business
- Yahoo
Tarsus to Participate in Upcoming Investor Conferences
IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: William Blair 45th Annual Growth Stock Conference on Tuesday, June 3rd, at 6:00 a.m. PT / 8:00 a.m. CT Jefferies Global Healthcare Conference on Wednesday, June 4th, at 12:45 p.m. PT / 3:45 p.m. ET Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9th, at 10:20 a.m. PT / 1:20 p.m. ET Live webcasts and additional information can be accessed on the events section of the Tarsus website. Replays will be available on the Tarsus website within 48 hours and will be archived for a limited time. About Tarsus Pharmaceuticals, Pharmaceuticals, Inc. applies proven science and new technology to revolutionize treatment for patients, starting with eye care. Tarsus is advancing its pipeline to address several diseases with high unmet need across a range of therapeutic categories, including eye care and infectious disease prevention. XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA approved in the United States for the treatment of Demodexblepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea, and TP-05 as an oral tablet for the potential prevention of Lyme disease. Media Contact:Adrienne KempSr. Director, Corporate Communications(949) 922-0801AKemp@ Investor Contact:David NakasoneHead of Investor Relations(949) 620-3223DNakasone@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
